vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and JBG SMITH Properties (JBGS). Click either name above to swap in a different company.
JBG SMITH Properties is the larger business by last-quarter revenue ($127.6M vs $83.5M, roughly 1.5× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -35.7%, a 42.5% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -2.5%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
JBG SMITH PropertiesJBGSEarnings & Financial Report
JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.
BLLN vs JBGS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $127.6M |
| Net Profit | $5.7M | $-45.5M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | -47.5% |
| Net Margin | 6.8% | -35.7% |
| Revenue YoY | 117.4% | -2.5% |
| Net Profit YoY | 138.3% | 24.0% |
| EPS (diluted) | $0.10 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $127.6M | ||
| Q3 25 | $83.5M | $123.9M | ||
| Q2 25 | — | $126.5M | ||
| Q1 25 | — | $120.7M | ||
| Q4 24 | — | $130.8M | ||
| Q3 24 | $38.4M | $136.0M | ||
| Q2 24 | — | $135.3M | ||
| Q1 24 | — | $145.2M |
| Q4 25 | — | $-45.5M | ||
| Q3 25 | $5.7M | $-28.6M | ||
| Q2 25 | — | $-19.2M | ||
| Q1 25 | — | $-45.7M | ||
| Q4 24 | — | $-59.9M | ||
| Q3 24 | $-14.9M | $-27.0M | ||
| Q2 24 | — | $-24.4M | ||
| Q1 24 | — | $-32.3M |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -47.5% | ||
| Q3 25 | 11.5% | -27.5% | ||
| Q2 25 | — | -18.4% | ||
| Q1 25 | — | -44.7% | ||
| Q4 24 | — | -53.6% | ||
| Q3 24 | -32.9% | -22.4% | ||
| Q2 24 | — | -24.3% | ||
| Q1 24 | — | -30.1% |
| Q4 25 | — | -35.7% | ||
| Q3 25 | 6.8% | -23.1% | ||
| Q2 25 | — | -15.2% | ||
| Q1 25 | — | -37.9% | ||
| Q4 24 | — | -45.8% | ||
| Q3 24 | -38.8% | -19.8% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | -22.2% |
| Q4 25 | — | $-0.76 | ||
| Q3 25 | $0.10 | $-0.48 | ||
| Q2 25 | — | $-0.29 | ||
| Q1 25 | — | $-0.56 | ||
| Q4 24 | — | $-0.70 | ||
| Q3 24 | $-1.47 | $-0.32 | ||
| Q2 24 | — | $-0.27 | ||
| Q1 24 | — | $-0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $75.3M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $1.2B |
| Total Assets | $327.5M | $4.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $75.3M | ||
| Q3 25 | $195.2M | $64.4M | ||
| Q2 25 | — | $61.4M | ||
| Q1 25 | — | $81.3M | ||
| Q4 24 | — | $145.8M | ||
| Q3 24 | — | $137.0M | ||
| Q2 24 | — | $163.5M | ||
| Q1 24 | — | $220.5M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | $-239.5M | $1.2B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | $-242.9M | $1.9B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.1B |
| Q4 25 | — | $4.4B | ||
| Q3 25 | $327.5M | $4.4B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $5.0B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $5.3B | ||
| Q1 24 | — | $5.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $73.3M |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $73.3M | ||
| Q3 25 | $13.8M | $8.9M | ||
| Q2 25 | — | $18.8M | ||
| Q1 25 | — | $12.9M | ||
| Q4 24 | — | $129.4M | ||
| Q3 24 | — | $26.4M | ||
| Q2 24 | — | $23.8M | ||
| Q1 24 | — | $37.0M |
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
JBGS
Segment breakdown not available.
